These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27715007)

  • 21. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine.
    Tournier BB; Steimer T; Millet P; Moulin-Sallanon M; Vallet P; Ibañez V; Ginovart N
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1819-34. PubMed ID: 23574629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
    Graham DL; Hoppenot R; Hendryx A; Self DW
    Psychopharmacology (Berl); 2007 Apr; 191(3):719-30. PubMed ID: 16835769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A highly D
    Galaj E; Bi GH; Klein B; Hempel B; Shaik AB; Gogarnoiu ES; Friedman J; Lam J; Rais R; Reed JF; Bloom SH; Swanson TL; Schmachtenberg JL; Eshleman AJ; Janowsky A; Xi ZX; Newman AH
    Neuropsychopharmacology; 2022 Dec; 47(13):2309-2318. PubMed ID: 35879349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
    Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH
    J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
    Schmidt HD; Pierce RC
    Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.
    Lv Y; Hu RR; Jing M; Zhao TY; Wu N; Song R; Li J; Hu G
    Acta Pharmacol Sin; 2019 May; 40(5):583-588. PubMed ID: 30224637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adverse effects of pramipexole on probability discounting are not reversed by acute D
    Orrù M; Strathman HJ; Floris G; Scheggi S; Levant B; Bortolato M
    Eur Neuropsychopharmacol; 2020 Mar; 32():104-119. PubMed ID: 31983530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects.
    Le Foll B; Sokoloff P; Stark H; Goldberg SR
    Neuropsychopharmacology; 2005 Apr; 30(4):720-30. PubMed ID: 15562293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of D3 receptor prevents changes in DAT and D3R expression in the mesolimbic dopaminergic circuit produced by social stress- and cocaine prime-induced reinstatement of cocaine-CPP.
    Guerrero-Bautista R; Franco-García A; Hidalgo JM; Fernández-Gómez F; Milanés MV; Núñez C
    J Psychopharmacol; 2020 Nov; 34(11):1300-1315. PubMed ID: 32648812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newly Developed Dopamine D
    Jordan CJ; Humburg BA; Thorndike EB; Shaik AB; Xi ZX; Baumann MH; Newman AH; Schindler CW
    J Pharmacol Exp Ther; 2019 Dec; 371(3):602-614. PubMed ID: 31562201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic doses of buspirone block D3 receptors in the living primate brain.
    Kim SW; Fowler JS; Skolnick P; Muench L; Kang Y; Shea C; Logan J; Kim D; Carter P; King P; Alexoff D; Volkow ND
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1257-67. PubMed ID: 24679922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lentiviral-mediated gene delivery reveals distinct roles of nucleus accumbens dopamine D2 and D3 receptors in novelty- and light-induced locomotor activity.
    Fernandes AR; Easton AC; De Souza Silva MA; Schumann G; Müller CP; Desrivières S
    Eur J Neurosci; 2012 Apr; 35(8):1344-53. PubMed ID: 22394078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats.
    Song R; Bi GH; Zhang HY; Yang RF; Gardner EL; Li J; Xi ZX
    Neuropharmacology; 2014 Feb; 77():398-405. PubMed ID: 24176392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D1 or D2 receptor antagonism within the basolateral amygdala differentially alters the acquisition of cocaine-cue associations necessary for cue-induced reinstatement of cocaine-seeking.
    Berglind WJ; Case JM; Parker MP; Fuchs RA; See RE
    Neuroscience; 2006; 137(2):699-706. PubMed ID: 16289883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.